The lawsuit covers investors who bought ADMA securities between August 9, 2024 and March 25, 2026, with an August 10, 2026 deadline to contact the firm.
The Schall Law Firm said it is reminding investors of a securities class action against ADMA Biologics, Inc. alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The case covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, and the firm urged affected shareholders to contact it before August 10, 2026. The complaint alleges ADMA engaged in an undisclosed related-party transaction, used channel stuffing to create the appearance of revenue, and failed to maintain appropriate internal controls. The firm said those issues rendered the company’s public statements false and materially misleading throughout the class period, and that investors suffered damages when the market learned the truth. It also noted that the class has not yet been certified, meaning investors are not represented unless and until certification occurs.